Sophie von Dyrander

“My decision to join Catenion? Here I found what I was looking for – high level strategy work, international clients and the team spirit of a smaller firm.”

Webpage Slider Anela Vukoja

„How can patients and the legislature steer the biopharmaceutical industry towards sustainable innovation?“

Dr. Anela Vukoja Associate
Graham Scholefield

“Sitting at the boundary between science and business is an incredibly rewarding experience”

Webpage Slider Pascal Joly

“At Catenion, I can put my scientific background in cell therapy and regenerative medicine to practical use and help bring innovative therapies to the market.“

Dr. Pascal Joly Associate
Webpage Slider Sarah Oelsner

“From bench to bedside and beyond: Translating inspiring science into innovative business strategies is a fascinating journey”

Dr. Sarah Oelsner Associate
Matthias Krings

“Change-Management is a team effort – let’s get started”

Dr. Matthias Krings Senior Partner
DLI 150326_Catenion_8264

“We help our clients to achieve best practise in managing R&D performance”

Markus Thunecke

“Is biopharma ready to embrace the new biology?”

Dr. Markus Thunecke Senior Partner
Webpage Slider Arno Heuermann

“Translating new technologies into viable business ideas”

Arno Heuermann COO, Partner, Managing Director
COG 150326_Catenion_0233

“I help R&D teams deliver on the promise of gene therapy”

Christian Elze

“China’s policy makers are making a concerted long-term effort to build a competitive biomedical innovation system – but R&D-based value creation
is only just beginning.”

Christian Elze Senior Partner
Webpage Slider Jonathan Vonnemann

“Uncovering the real value of technologies for our clients by seeing through the smoke and mirrors of the industry is just one of the fascinating aspects of working at Catenion”


In Vivo Biopharma RD Productivity-Growth 2017

This is our fourth annual survey of pharma R&D productivity. Last year we noted that there has been a year-on-year increase in R&D productivity to the tune of 46% from 2014 to 2016. However this trend has not continued in 2017 …

Financier – M&A in biopharma – why bigger is not better

Numerous studies by academics and consultants demonstrate that M&A, on average, destroys value. A recent study performed on the Russe II 3000 index from 2001 to 2013 shows that most M&A is dilutive to earnings growth over an extended period post-merger. …
Download this article

Meet Us

March 6 - 9, 2018

Pharma PPM Toolbox, workshop and conference, London

Jan 20, 2018

The New York Academy of Sciences, RiskyBusiness, NewYork

Nov. 13-15, 2017


Nov. 8th, 2017

Tokyo University – Cultural Challenges in Translational Research

Nov. 8, 2017

University of Cambridge, Career Event, Cambridge, UK

Nov. 6-8, 2017

Bio-Europe, Berlin

Nov. 5, 2017

Bio-Europe Catenion Welcome Reception, PanAm Lounge Berlin

Oct. 28, 2017

University of Oxford, Career Fair, Oxford, UK

Sep. 25, 2017

Cell & Gene Terapy CEO, Boston

Sep. 20-21, 2017

Immuno-oncology Frontiers, Berlin